Positions

Associate Professor of Surgery

Michael E. DeBakey Department of Surgery
David J. Sugarbaker Division of Thoracic Surgery
Baylor College of Medicine
HOUSTON, Texas United States

Director

Systems Onco-Immunology Lab

Member

Dan L Duncan Comprehensive Cancer Center

Addresses

Laboratory (Lab)

Alkek Building for Biomedical Research
Houston, TX 77030
United States

Education

Research Fellowship at Systems Biology, UT MD Anderson Cancer Center

HOUSTON, Texas United States

Clinical Fellowship at Thoracic Surgery, Center for Lung Cancer, National Cancer Center

Goyang, Republic of Korea

PhD from Yonsei University College of Medicine

Seoul, Republic of Korea

Residency at Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine

Seoul, Republic of Korea

MD from Yonsei University College of Medicine

Seoul, Republic of Korea

Honors & Awards

PEAR (Professional Educator Appreciation and Recognition) Award

Baylor College of Medicine (08/2022)

O.H. Frazier, M.D. Innovation Awards

Baylor College of Medicine (10/2022)

Waun Ki Hong Memorial Award

Severance Alumni Association of USA (11/2022)

The Power of Professionalism (POP) Award

Baylor College of Medicine (03/2023)

Michael E. DeBakey Faculty Research Award

BAYLOR COLLEGE OF MEDICINE (07/2021 - 06/2022)

Professional Interests

• Systems Onco-Immunology
• Malignant pleural mesothelioma
• Lung cancer
• Single-Cell Multi-Omics
• Immunoproteogenomics

Professional Statement

Dr. Lee is a tenured Associate Professor of the Michael E. DeBakey Department of Surgery at Baylor College of Medicine (BCM). He has more than ten years of experience treating lung cancer and esophageal cancer as an attending thoracic surgeon, three years of research in the Department of Systems Biology at UT MD Anderson Cancer Center, and eight years of immunology research in the Michael E. DeBakey Department of Surgery at BCM. Dr. Lee is Director of the Systems Onco-Immunology Lab (SOIL) at BCM, in which the 10XGenomics Chromium X and Chromium Controller are equipped to generate single-cell libraries for single-cell multi-omics platforms, including single-cell RNA sequencing with TCR analysis. He is particularly enthusiastic about “systems onco-immunology,” with specific experience in comprehensively integrating high-dimensional single-cell time-of-flight mass cytometry (CyTOF), imaging mass cytometry (IMC), mass spectrometry–based immunopeptidomics, and single-cell multi-omics data. He has applied innovative immunoproteomic and immunogenomic approaches to this framework to understand the mechanisms underlying clinical outcomes and primary or acquired resistance to immunotherapy in these diseases. He continues to characterize and unravel the cellular immune network by analyzing human and mouse single-cell data, correlating immune composition with immunogenomic determinants to predict clinical prognosis and response to checkpoint immunotherapy.
Dr. Lee's strongest expertise lies in grasping the clinical implications of translational research and bridging our advancing science to meet the critical needs within immuno-oncology. His overarching goals are to identify potential therapeutic targets to overcome resistance to checkpoint immunotherapy and to investigate the cellular mechanism of tumor immunity and autoimmunity after immunotherapy by applying “comprehensive and integrated systems immunology” approaches.

Websites

Selected Publications

• Hyun-Sung Lee, Hee-Jin Jang, Jong Min Choi, Jun Zhang, Veronica Lenge de Rosen, Thomas M. Wheeler, Ju-Seog Lee, Thuydung Tu, Peter T. Jindra, Ronald H. Kerman, Sung Yun Jung, Farrah Kheradmand, David J. Sugarbaker, and Bryan M. Burt "Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma." Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma JCI Insight. 2018 Apr 5;
• Jang HJ, Truong CY, Lo EM, Holmes HM, Ramos D, Ramineni M, Lee JS, Wang DY, Pietropaolo M, Ripley RT, Burt BM, Lee HS "Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant Mesothelioma." Ann Thorac Surg. 2021 Sep;
• Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, Splawn T, Espinoza M, Almarez M, Hosey L, Jo E, Hilsenbeck S, Amos CI, Ripley RT, Burt BM "A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma." Clin Cancer Res. 2023 Feb;29(3):248-559. Pubmed PMID: 36469573
• Jang HJ, Lee HS, Yu W, Ramineni M, Truong CY, Ramos D, Splawn T, Choi JM, Jung SY, Lee JS, Wang DY, Sederstrom JM, Pietropaolo M, Kheradmand F, Amos CI, Wheeler TM, Ripley RT, Burt BM "Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment." Cancer Res. 2022 Jul;82(14):2593-2609. Pubmed PMID: 35709756

Memberships

Dan L Duncan Comprehensive Cancer Center member

Research Member (03/2023)

Funding

Individual Investigator Research Awards 2020

(03/01/2020 - 02/29/2024) Grant funding from CPRIT

the Cancer Prevention and Research Institute of Texas

Investigator-Initiated Sponsored Research

(06/01/2021 - 05/31/2024) Grant funding from Samyang Biopharm USA

Therapeutic targeting of MIC-NKG2D signal to overcome resistance to checkpoint immunotherapy

Peer Reviewed Cancer Research Program Impact Award

Grant funding from Department Of Defense